{'fraction_non_alphanumeric': 0.03414996288047513, 'fraction_numerical': 0.030438010393466965, 'mean_word_length': 5.673267326732673, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Endothelin-converting enzyme inhibitors and their potential for cardiovascular and renal therapeutics

Inhibition of endothelin-converting enzyme (ECE) will reduce the levels of endothelin-1 (ET-1). A pathological effect for ECE/ET-1 on the human cardiovascular system has been suggested in systemic hypertension, pulmonary hypertension, chronic heart failure, myocardial infarction, atherosclerosis and restenosis. On the kidney, ECE/ET-1 may have a pathological role in acute and chronic renal failure, IgA nephropathy, cyclosporin toxicity, chronic renal allograft rejection and autosomal-dominant polycystic kidney disease. ECE-1 inhibitors have therapeutic potential in all of these cardiovascular and renal conditions. Selective non-peptide ECE inhibitors that have been patented include FR-901533, PD-069185, CGS-35066, SM-19712, CGS-30084 and Ro0677447. Studies with animal disease models suggest that ECE inhibitors may have a role in the treatment of pulmonary hypertension, myocardial infarction, cardiac hypertrophy and failure, restenosis and acute renal failure. There are four isoforms of ECE-1 with similar catalytic activity but differences in tissue and cellular localisation. The development of selective inhibitors of the ECE-1 isoforms may give better targeting of function/disease than the presently available ECE inhibitors.